Bio-Techne (NASDAQ:TECH) reports Q3 earnings, revenue climbs 2% to $303.4M
Full story: https://grafa.com/news/bio-techne--nasdaq-tech--reports-q3-earnings--revenue-climbs-2--to--303-4m-216191
Bio-Techne Corporation (NASDAQ:TECH) has released its financial outcomes for the third quarter ending March 31, 2024.
The company reported an organic revenue increase of 2% (3% reported) leading to a total of $303.4 million.
Despite the revenue increase, GAAP earnings per share (EPS) dropped to $0.31 from the previous year’s $0.43, with an adjusted EPS of $0.48 compared to last year's $0.53.
A significant highlight from the quarter is the 10% organic segment growth (16% reported) in Diagnostics & Genomics attributed to strong commercial execution.
Meanwhile, the company saw an uptick in cash flow generated from operations, which reached $223.5 million, marking a 31% increase from the year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Grafa·05-01Read the full story https://grafa.com/news/bio-techne--nasdaq-tech--reports-q3-earnings--revenue-climbs-2--to--303-4m-2161911Report